Unaudited Standalone & Consolidated Financial Result of the company for the quarter ended December 31, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.1 pts more than Nifty Microcap 250 and 4.8 pts more than its Trading & Distributors peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Genpharmasec Limited announced its Q3 FY26 and 9M FY26 results on February 9, 2026. On a standalone basis, quarterly PAT came in at Rs. 75.64 lakhs versus Rs. 110.50 lakhs in Q3 FY24, while 9M FY26 PAT stood at Rs. 313.15 lakhs versus Rs. 267.30 lakhs in the prior-year period, showing modest growth. On a consolidated basis, however, results were dragged into losses due to the newly acquired 70% subsidiary, Derren Healthcare Private Limited, which reported a net loss of Rs. 304.41 lakhs for 9M FY26 since becoming a subsidiary on July 25, 2025. Consolidated PAT attributable to parent shareholders for 9M FY26 turned negative, swinging sharply from a profit of Rs. 181.25 lakhs in the prior-year period. The company also made a retrospective accounting policy change, reclassifying certain equity shares from Inventories to Financial Investments measured at FVOCI, reducing inventory by Rs. 89.32 lakhs with a Rs. 19.67 lakh hit on total comprehensive income. The statutory auditor has changed from Abhishek S Tiwari & Associates to Bilimoria Mehta & Co., which issued an unmodified review opinion.
Despite healthy standalone operations, the consolidated picture turned negative because of significant losses at the recently acquired Derren Healthcare subsidiary, which may weigh on the stock in the short term. Shareholders should monitor subsidiary performance closely as it is currently a drag on group profitability.